Abstract-Inflammatory responses are associated with the genesis and progression of end-organ damage (EOD) in hypertension. A role for the ␣7 nicotinic acetylcholine receptor (␣7nAChR) in inflammation has recently been identified. We tested the hypothesis that ␣7nAChR dysfunction contributes to hypertensive EOD. In both spontaneously hypertensive rats (SHRs) and rats with abdominal aorta coarctation-induced hypertension, atropine-induced tachycardia was blunted compared with normotensive controls. Both models of hypertension were associated with deficits in expression of the vesicular acetylcholine transporter and the ␣7nAChR in cardiovascular tissues. In hypertension induced by abdominal aorta coarctation, deficits in aortic vesicular acetylcholine transporter and ␣7nAChR were present both above and below the coarctation site, indicating that they were independent of the level of arterial pressure itself. Hypertension in 40-week-old SHRs was associated with cardiac and aortic hypertrophy. Morphological abnormalities consistent with EOD, along with elevated tissue levels of proinflammatory cytokines (tumor necrosis factor-␣, interleukin-1␤, and interleukin-6) were observed in the heart, kidney, and aorta. Chronic treatment of SHRs with the ␣7nAChR agonist PNU-282987 relieved EOD and inhibited tissue levels of proinflammatory cytokines and activation of nuclear factor B. Greater serum levels of proinflammatory cytokines and more severe damage in the heart, aorta, and kidney were seen in ␣7nAChR Ϫ/Ϫ mice subjected to 2-kidney-1-clip surgery than in wild-type mice. A deficit in the cholinergic anti-inflammatory pathway appears to contribute to the pathogenesis of EOD in models of hypertension of varying etiology. This pathway may provide a new target for preventing cardiovascular disease resulting from hypertension. (Hypertension. 2011;57:00-00.) • Online Data Supplement Key Words: acetylcholine Ⅲ ␣7 nicotinic acetylcholine receptor Ⅲ inflammation Ⅲ hypertension Ⅲ end-organ damage H ypertension is a major risk factor for myocardial infarction, heart failure, stroke, and kidney dysfunction. Endorgan damage (EOD), including cardiac hypertrophy and myocyte dysfunction, vascular remodeling, and renal lesions, is a crucial mediatory link between hypertension and the development of these cardiovascular events. 1 Therefore, a better understanding of the mechanisms leading to hypertensive EOD could provide new avenues for prevention of cardiovascular events. Inflammation is very important in the genesis and development of EOD. 2,3 Furthermore, the reninangiotensin system can contribute to EOD, at least partly by promoting inflammation. 4 -7 However, cardiovascular inflammation and EOD can also occur without renin-angiotensin system activation, 8 so other mechanisms must also operate.
H ypertension is a major risk factor for myocardial infarction, heart failure, stroke, and kidney dysfunction. Endorgan damage (EOD), including cardiac hypertrophy and myocyte dysfunction, vascular remodeling, and renal lesions, is a crucial mediatory link between hypertension and the development of these cardiovascular events. 1 Therefore, a better understanding of the mechanisms leading to hypertensive EOD could provide new avenues for prevention of cardiovascular events. Inflammation is very important in the genesis and development of EOD. 2, 3 Furthermore, the reninangiotensin system can contribute to EOD, at least partly by promoting inflammation. 4 -7 However, cardiovascular inflammation and EOD can also occur without renin-angiotensin system activation, 8 so other mechanisms must also operate.
Recent evidence indicates that neuronal 9 -11 cholinergic systems influence inflammatory responses by controlling the release of tumor necrosis factor (TNF)-␣, interleukin-(⌱L)-1␤, and IL-6 and that nonneuronal acetylcholine synthesis and release machinery are downregulated in inflammation. 12 Vagal activation can suppress inflammation. For example, vagal stimulation blunted the release of TNF-␣ from macrophages and decreased mortality induced by endotoxin in rats. 10 The anti-inflammatory actions of vagal efferent activity appear to be mediated chiefly by acetylcholine (ACh) acting at the ␣7 nicotinic acetylcholine receptor (␣7nAChR). 11, [13] [14] [15] The vesicular acetylcholine transporter (VAChT) mediates the loading of ACh into secretory organelles in neurons, thereby making ACh available for release. 16, 17 Thus, if impairment of cholinergic antiinflammatory pathways contributes to development of EOD during hypertension, then dysfunction of the ␣7nAChR and/or the VAChT seems likely.
Hypertension is associated with impaired arterial baroreflex function. 18 The high frequency component of heart rate variability is reduced in human hypertension, indicating impairment of cardiac vagal drive. 19 Importantly, impaired baroreflex function and reduced vagal tone are associated with increased risk for cardiovascular disease, 19 but the mechanistic link between reduced vagal tone and increased cardiovascular risk is largely unknown. In the present study, we tested the hypothesis that dysfunction in ␣7nAChR-mediated signaling contributes to development of EOD in hypertension. If this mechanism is important, it should operate across a range of models of hypertension of differing etiology. Thus, we used 3 hypertensive animal models, including spontaneously hypertensive rats (low renin), pressure-overload hypertensive rats (coarctation hypertension, high renin), and 2-kidney-1-clip (2K1C) surgery-induced hypertension (high renin).
Methods Animals
Male Sprague-Dawley rats, Wistar-Kyoto (WKY) rats, and spontaneously hypertensive rats (SHRs) and ␣7nAChR Ϫ/Ϫ mice were housed in a 12/12-hour light/dark cycle with free access to food and water. All the animals used in this work received humane care in compliance with the institutional animal care guidelines and the Guide for Care and Use of Laboratory Animals published by the National Institutes of Health.
Abdominal Aorta Coarctation-Induced Hypertension in Rats
Partial abdominal aorta coarctation was produced as described previously 20 to induce hypertension in the upper part of the systemic circulation (see the online Supplement available at http://hyper. ahajournals.org).
Renovascular Hypertension in Mice

2K1C hypertension was induced in male ␣7nAChR
Ϫ/Ϫ mice and wild-type (WT) mice (20 to 25 g), as described previously. 21, 22 Silver clips (0.12-mm opening width, Exidel SA, Lausanne, Switzerland) were used to narrow the left renal artery (see the online Supplement).
Blood Pressure and Heart Rate Measurement
Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) were continuously recorded in conscious rats as described previously (see the online Supplement). 23,24
Morphological Examination
Injury to heart, kidney, and aorta was examined morphologically, as described previously. 25 Glomerular sclerosis score provided a semiquantitative evaluation of glomerular damage in the right kidney, as previously described (see the online Supplement). 26
RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction Analysis
These analyses were performed as described in previous publications (see the online Supplement). 27,28
Protein Extraction and Western Blot Analysis
Whole or nuclear protein extractions and Western blot analysis of ␣7nAChR, VAChT, and nuclear factor (NF)-B were performed as described previously (see the online Supplement). 27,28
Quantification of Tissue Inflammatory Factors
Levels of TNF-␣, IL-1␤, and IL-6 were determined by ELISA, as described previously (see the online Supplement). 28
Histological Analysis by Light and Electron Microscopy
These analyses were performed as described previously (see the online Supplement). 25
Chronic Treatment With PNU-282987
Four groups of rats (nϭ8 in each) were included in this experiment: WKY rats, WKY rats treated with PNU-282987, SHRs, and SHRs treated with PNU-282987. PNU-282987 is a selective agonist of the ␣7nAChR. From 36 weeks of age, PNU-282987 (0.38 mg/kg, IP; Sigma) 29 or its vehicle (0.4% DMSO in saline) was administered daily for 28 days. Rats were then killed under deep anesthesia, and the right kidney, aorta, and heart were excised for Western blot, ELISA, and histological analyses.
Statistical Analysis
All values are expressed as meansϮSEM. Results were analyzed by paired (within-group) or unpaired (between 2 groups) Student t test or ANOVA, followed by Tukey test (among 3 or more groups). Two-sided PϽ0.05 was considered statistically significant.
Results
Basal Arterial Pressure and Vagal Tone in SHRs
To assess vagal tone, the cardiovascular effects of atropine were determined in SHRs and age-matched WKY rats (Table  S1 in the online Supplement). Atropine significantly increased HR but not SBP or DBP. Atropine-induced tachycardia was significantly less in hypertensive SHRs than WKY rats (ie, at 20 and 40 but not 4 weeks of age), indicating a deficit in cardiac vagal tone in hypertensive SHRs. Baroreceptor reflex sensitivity, which also reflects vagal tone, was also reduced in SHRs at 20 and 40 but not 4 weeks of age (Table S2) .
Gene and Protein Expression of VAChT and ␣7nAChR in Heart, Kidney, and Aorta of SHRs
To evaluate cholinergic function in SHRs at the molecular level, we assessed protein expression of the VAChT and ␣7nAChR. VAChT protein expression and both mRNA and protein expression of the ␣7nAChR were all less in the heart, kidney, and aorta of SHRs than in age-matched WKY rats at 20 and 40 weeks of age but not at 4 weeks of age ( Figure 1 ).
Vagal Tone, ␣7nAChR, and VAChT in Coarctation-Induced Hypertension Rats
To examine the role of increased arterial pressure itself in the altered expression of ␣7nAChR and VAChT in hypertension, expression of these factors was examined in aorta coarctation-induced hypertension (CH) rats. As expected, 16 weeks after surgery to induce CH, SBP measured from the carotid artery was significantly greater in CH rats compared with sham-operated controls (Table S3) , whereas SBP measured from the femoral artery was similar in the 2 groups of rats (Table S3) . That is, in CH, SBP was increased within the thoracic aorta but not the abdominal aorta. Nevertheless, ␣7nAChR and VAChT protein expression were less in both the thoracic and abdominal aorta of CH rats compared with sham-operated controls (Figure 2 ). Atropine caused less tachycardia in CH rats than in sham-operated rats (Table S3) .
Cardiovascular Inflammation and EOD in SHRs
In WKY, levels of ⌱L-1␤ and TNF-␣, but not IL-6, varied among the heart, kidney, and aorta. Compared with agematched WKY rats, levels of ⌱L-1␤, IL-6, and TNF-␣ were all greater in the heart, kidney, and aorta of 40-week-old SHRs ( Figure 3A through 3C) . Evidence of EOD, including cardiac hypertrophy ( Figure 3D ), renal atrophy ( Figure 3E ), and aortic hypertrophy ( Figure 3F ), was observed in SHRs.
Inflammation and EOD Induced by Hypertension in ␣7nAChR ؊/؊ Mice
To further investigate the role of the ␣7nAChR in hypertensive EOD, ␣7nAChR Ϫ/Ϫ mice and WT controls were rendered hypertensive by clipping 1 renal artery. After sham surgery, arterial pressure and levels of proinflammatory cytokines were similar in the 2 genotypes. Eight weeks after the 2K1C operation, SBP was similar in WT and ␣7nAChR Ϫ/Ϫ mice, albeit within the hypertensive range (145 to 150 mm Hg). At this time point, levels of serum ⌱L-1␤ , IL-6, and TNF-␣ were greater in ␣7nAChR Ϫ/Ϫ mice compared with WT mice (Figure 4 ).
There was evidence of more severe EOD in ␣7nAChR 
␣7nAChR
Ϫ/Ϫ mice compared with WT controls. In 2K1C-WT mice, renovascular hypertension was associated with irregular arrangement and mild degeneration of cardiac myocytes, vagueness of the cardiac myocyte mitochondrial membrane, irregular arrangement of vascular smooth muscle cells, mild degeneration of vascular endothelial cells, focal degeneration of the renal tubular epithelium, and mild hyperplasia of the glomerular mesangium. These lesions were considerably more severe in 2K1C-␣7nAChR Ϫ/Ϫ mice than WT mice ( Figure 5 ).
Effects of PNU-282987 on Cardiovascular Inflammation and EOD in SHRs
In SHRs, no significant changes in SBP, DBP, or HR were observed after single acute intravenous doses of PNU-282987 of 0.38 or 3.8 mg/kg (Table S4 ). Chronic PNU-282987 administration (0.38 mg/kg per day for 28 days, IP) in SHRs also did not significantly alter arterial pressure or heart rate ( Table S5) or expression of ␣7nAChR protein in heart, kidney, aorta, or macrophages ( Figure S1 in the online Supplement). However, levels of some inflammatory factors in tissues of SHRs were reduced by PNU-282987 treatment. Levels of IL-1␤, IL-6, and TNF-␣ in SHR tissues were greater than those in WKY. Lesser levels of these factors were observed in the aorta of PNU-282987-treated SHRs compared with vehicle-treated SHRs. In the heart, lesser levels of TNF-␣ were found in PNU-282987-treated SHRs compared with vehicle-treated SHRs, whereas levels of IL-1␤ and IL-6 were not significantly altered by PNU-282987 treatment. In the kidney, lesser levels of IL-1␤ and IL-6, but not TNF-␣, were observed in PNU-282987-treated SHRs compared with vehicle-treated SHRs. There were no significant differences in the levels of these proinflammatory cytokines between WKY and WKY treated with PNU-282987 ( Figure 6 ).
At the level of light microscopy, left ventricular damage in vehicle treated SHRs was characterized by irregular arrange- ment of cardiac myocytes and eosinophilic or granular degeneration in some cardiac myocytes ( Figure 7 ). Thickening of the aortic wall was observed, associated with increased collagen in the media, an incomplete intima and loss of endothelial cells. Renal damage was characterized by interstitial inflammatory cell infiltration, fibroblast hyperplasia, mesangial matrix proliferation, and afferent arteriole thickening. These lesions in the left ventricle, aorta, and kidney were much less prominent in SHRs treated with PNU-282987 ( Figure 7 ). PNU-282987 treatment did not induce morphological changes in WKY rats. At the level of transmission electron microscopy, mitochondria from the left ventricle of vehicle-treated SHRs were obviously swollen and loosely arranged, whereas mitochondrial membranes were vague or partly ruptured and cristae were clearly loose and dissolved ( Figure 7 ). The dark Z-lines within the sarcomeres were disjointed and blurred, and some myofibrils and sarcomeres were either not present or disorganized. In contrast, mitochondria in the ventricular myocardium of SHRs treated with PNU-282987 were more densely packed and had more compact cristae, whereas myofilaments and sarcomeres were arranged in a relatively normal fashion. In the kidney of vehicle-treated SHRs, glomerular basement membrane thickening, focal mesangial matrix accumulation, and widening or partial effacement of podocyte foot processes were observed. These ultrastructural features were greatly ameliorated by PNU-282987 treatment. Similar beneficial effects of PNU-282987 treatment were observed in SHR aortas (Figure 7 ).
Effects of PNU-282987 on NF-B Signaling
To further explore the intracellular mechanisms underpinning the anti-inflammatory effects of PNU-282987, we investigated the effects of this agent on NF-B signaling in SHRs and WKY rats (Figure 8 ). Compared with WKY rats, the nuclear NF-B p65 subunit was conspicuously enhanced in tissues of SHRs, whereas the cytosolic IB was decreased, indicating the NF-B system was activated in SHRs. Treatment of PNU-282987 attenuated nuclear NF-B p65 subunit levels and upregulated cytosolic IB levels in SHRs (Figure 8 ). These observations indicate that activation of the ␣7AChR by PNU-282987 suppresses inflammation, at least partly, through inhibiting activation of the NF-B signaling pathway.
Discussion
Three major new findings arose from the present work. Firstly, vagal tone and expression of both the VAChT and the ␣7nAChR were significantly less in both CH rats and SHRs compared with normotensive control rats. Importantly, in CH, impaired VAChT and ␣7nAChR expression was observed in the aorta both above and below the coarctation. Thus, ␣7nAChR-mediated signaling is impaired systemically in multiple forms of hypertension. Secondly, serum levels of proinflammatory cytokines and EOD in 2K1C hypertension were greater in ␣7nAChR Ϫ/Ϫ mice than WT controls. Thus, inflammation and EOD are enhanced in the absence of ␣7nAChR-mediated signaling. Thirdly, we found that the increased tissue levels of proinflammatory cytokines and the EOD observed in 40-week-old SHRs could be blunted by chronic treatment with the selective ␣7nAChR-agonist PNU-282987. Thus, EOD can be blunted by enhancing ␣7nAChR-mediated signaling. These ␣7nAChR-mediated beneficial effects were associated with its ability to attenuate activation of the NF-B signaling pathway in hypertension. Collectively, these findings indicate that diminished ␣7nAChR signaling is a major mechanism in the pathogenesis of cardiovascular inflammation and EOD in hypertension. The 
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significance of these findings is 2-fold. Firstly, they provide a plausible mechanistic explanation for the association of reduced vagal tone with increased cardiovascular risk. 19 Secondly, they indicate that the ␣7nAChR may be a therapeutic target for prevention of hypertensive EOD. We evaluated the function of cholinergic antiinflammatory pathways using multiple methods. Firstly, we determined the tachycardic response to atropine, a classic index of cardiac vagal tone. 30, 31 Although the response to atropine is mediated by blockade of muscarinic receptors rather than nicotinic receptors, it provides an integrated measure of basal ACh release and muscarinic receptor signaling in the heart. In accord with previous studies indicating impaired arterial baroreflex function and depressed baroreflex-mediated cardiac vagal responsiveness in essential hypertension, 23,32-35 the tachycardia induced by atropine was significantly decreased in hypertensive SHRs compared with WKY rats and in rats with CH compared with sham-operated controls. Our present findings provide a mechanistic explanation for this finding, because cardiac VAChT expression was greatly blunted in both of these models of hypertension, consistent with the proposition that they are associated with reduced storage and release of ACh in the heart. 36 Interestingly, the deficit in VAChT expression was not confined to the heart but was also observed in the kidney and aorta, tissues devoid of direct parasympathetic innervation. Thus, hypertension of multiple etiology appears to be associated with a systemic diminution in both neuronal and nonneuronal cholinergic signaling.
There is strong evidence that the ␣7nAChR, expressed in primary immune cells and perhaps also in peripheral tissues, is a pivotal mediator of the cholinergic anti-inflammatory pathway. 11, 37 To understand the impact of arterial pressure per se on cholinergic signaling, ␣7nAChR and VAChT expression were examined in multiple models of hypertension. Firstly, expression of the ␣7nAChR and VAChT in the heart, kidney, and aorta was compared between age-matched WKY rats and SHRs. ␣7nAChR and VAChT expression in these tissues was consistently less in SHRs with established hypertension (20 and 40 weeks of age) than in age-matched WKY rats, but not in prehypertensive SHRs (4 weeks of age). These observations support the concept that it is hypertension, rather than other factors associated with the genotypic differences between SHRs and WKY rats, that leads to downregulation of the ␣7nAChR and VAChT in SHRs. To further assess the influence of arterial pressure on ␣7nAChR and VAChT expression, a pressure-overload rat model was prepared by abdominal arterial coarctation. In this model, ␣7nAChR and VAChT were equally downregulated in aortic segments upstream and downstream of the coarctation. Thus, rather than exerting a local effect dependent on the level of arterial pressure within each specific vascular territory, hypertension appears to exert a systemic effect to suppress cholinergic signaling. It is well accepted that chronic hypertension results in decreased vagal function. 33, 38 The finding that both vagal tone and expression of the VAChT were reduced, in both SHRs and CH rats with established hypertension, raises the possibility that the vagal dysfunction induced by hypertension might subsequently result in downregulation of the ␣7nAChR. However, it is difficult to envisage how vagal dysfunction could affect cholinergic signaling in tissues devoid of parasympathetic innervation such as the kidney and aorta. One possible explanation is the existence of nonneuronal cholinergic anti-inflammatory pathways in these tissues. It is well established that nonneuronal cholinergic systems contribute to multiple cellular functions including proliferation, differentiation, migration, and ion and water movement. 39 -42 Dysfunction of nonneuronal cholinergic systems appears to be involved in the pathogenesis of many diseases, including some inflammatory conditions. 39 -42 Our findings in the kidney and aorta suggest the existence of nonneuronal cholinergic anti-inflammatory pathways in these tissues, which limit signaling through proinflammatory cytokines and consequently organ damage.
The ␣7nAChR has been proposed as a therapeutic target for control of inflammatory disorders. [43] [44] [45] [46] Therefore, we investigated the role of the ␣7nAChR in inflammation and EOD in renovascular hypertension using ␣7nAChR Ϫ/Ϫ mice. After induction of 2K1C hypertension, ␣7nAChR Ϫ/Ϫ mice displayed greater serum levels of proinflammatory cytokines (⌱L-1␤ , IL-6, and TNF-␣) and more severe EOD than WT mice. Thus, the ␣7nAChR exerts an anti-inflammatory influence in 2K1C hypertension. We also examined the effects of chronic treatment of SHRs with PNU-282987, a selective ␣7nAChR agonist. 47 Consistent with previous studies, levels of IL-6, IL-1␤, and TNF-␣ in aorta and plasma were greater in adult SHRs than in age-matched WKY rats. 48 Similar observations have been made in hypertensive patients. 49 Our important new finding was that treatment with PNU-282987 did not reduce blood pressure but decreased the levels of these inflammatory factors in SHR tissues in most cases and greatly attenuated EOD as assessed by both light and electron microscopy. Thus, pharmacological rescue of the deficit in ␣7nAChR signaling in SHRs has anti-inflammatory effects. Collectively, these data from ␣7nAChR Ϫ/Ϫ mice and SHRs treated with PNU-282987 provide compelling evidence for a role of the cholinergic anti-inflammatory pathway, mediated via the ␣7nAChR, in the pathogenesis of hypertensive EOD.
An association between the ␣7nAChR and the NF-B signaling pathway has been recently reported in neuronal cells. 50 Our finding that chronic treatment of SHRs with the ␣7nAChR agonist PNU-282987 inhibited activation of NF-B in heart, kidney, and aorta provides the first evidence for a critical role of the NF-B signaling pathway in the anti-inflammatory influence of the ␣7nAChR in hypertension.
The importance of the renin-angiotensin system in cardiovascular disease is well established. 51 With regard to the role of autonomic nervous system in hypertensive EOD, most attention has focused on the sympathetic nervous system, 52 with little attention paid to the parasympathetic nervous system. In this study, we provide strong evidence that dysfunction of ␣7nAChR-mediated signaling, likely attributable to the combined effects of impaired ACh release and downregulation of the ␣7nAChR, contributes to EOD in multiple forms of hypertension through disinhibition of proinflammatory cascades.
Perspectives
Our findings provide a plausible mechanistic explanation for the well established association between impaired cardiac vagal tone, as evidence by reduced heart rate variability, and increased cardiovascular risk. 19 That is, reduced heart rate variability may be an epiphenomenon associated with impaired activation of anti-inflammatory pathways downstream from ␣7nAChR activation. Activation of the ␣7nAChR may therefore represent a novel therapeutic strategy for limiting EOD in hypertension. 
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None. were recorded during the period one hour before and one hour after drug administration 32 in conscious SHR.
33
Baroreflex sensitivity (BRS), which has been shown to mainly reflect vagal tone, [3] [4] [5] was 34 measured in rats using the method described previously. 6, 7 The principle of this method is 35 to measure the prolongation of heart period in response to an elevation of SBP. A bolus 36 injection of phenylephrine (1-5 μg/kg) was given to raise SBP between 20 and 40 mmHg. 37 The relationship between heart period and SBP was determined using linear regression 38 analysis to provide BRS (msec/mmHg).
39
Histological analysis by light and electron microscopy 40 The fresh heart, kidney and aorta were immersed in a 4% solution of paraformaldehyde in 41 PBS and were fixed in this solution for 24 h. Japan).
7
Morphological examination 8 The animals were weighed and anesthetized with pentobarbital (40 mg/kg, i.p). The 9 thoracic and peritoneal cavities were immediately opened. The right kidney, aorta and 10 heart were excised and rinsed in cold physiological saline. The right kidney and the heart 11 were gently blotted dry so that kidney weight and left ventricular weight were determined. 12 At the same time, the aorta was cleaned of adhering fat and connective tissue. A leupeptin (50 µg/ml), aprotinin (25 µg/ml), pesptatin A (10μg/ml) and dithiothreitol 43 (DTT2 mmol/L). The supernatant was obtained by centrifugation at 11,000 g for 15 min 44 at 4°C. For studies of NF-κB signaling, nuclear protein was extracted using a Nuclear Rats: Forty-week-old SHR and WKY rats were anesthetized with pentobarbital (40 14 mg/kg, i.p). Then, the heart, kidney and aorta were harvested and washed three times in 15 PBS, homogenized, centrifuged at 11,000 g at 4 o C for 10 min, and the supernatant was the TNF-α, IL-6 and IL-1β assays were, respectively, 5.1, 1.6 and 3.0 pg/ml. Intra and 28 interassay coefficients of variation for all assays was ≤10%. 
